Contact Us / Request a Quote Download Manuals
Advanced Cell Diagnostics Advanced Cell Diagnostics

Search form

Please sign in
  • Log In
  • Register
  • How to Order
  • What to Buy
0 My Cart
X

You have no items in your shopping cart.

Menu
X
  • Products +
    RNAscope™/BaseScope™/ miRNAscope™
    +
    • Assay Selection Guide
    Target Probes
    +
    • All About Probes
    • Catalog Probes
    • Probe Sets
    • New Probe Request
    Manual Assays
    +
    RNAscope™ Chromogenic
    • Overview
    • RNAscope™ 2.5 HD Assay-Brown
    • RNAscope™ 2.5 HD Assay-Red
    • RNAscope™ 2.5 HD Duplex Assay
    RNAscope™ Multiplex Fluorescent
    • Overview
    • RNAscope™ HiPlex v2 Assay
    • RNAscope™ Multiplex Fluorescent V2
    BaseScope™
    • Overview
    • BaseScope™ Assay Red
    • BaseScope™ Duplex Assay
    miRNAscope™
    • Overview
    • miRNAscope™ Assay red
    • RNAscope™ Plus smRNA-RNA Assay
    DNAscope™
    • Overview
    • DNAscope™ Duplex Assay
    Automated Assays
    +
    For Lunaphore COMET™
    • RNAscope™ HiPlex Pro for COMET™
    For Leica systems
    • Overview
    • RNAscope™ 2.5 LS Assay-Brown
    • RNAscope™ 2.5 LS Assay-Red
    • RNAscope™ 2.5 LS Duplex Assay
    • RNAscope™ Multiomic LS Assay
    • RNAscope™ 2.5 LS Fluorescent Multiplex Assay
    • RNAscope™ 2.5 LSx Reagent Kit-BROWN
    • RNAscope™ 2.5 LSx Reagent Kit-RED
    • BaseScope™ LS Reagent Kit – RED
    • miRNAscope LS Reagent Kit Red
    • RNAscope™ Plus smRNA-RNA LS Assay
    Roche DISCOVERY ULTRA system
    • Overview
    • RNAscope™ VS Universal HRP
    • RNAscope™ VS Universal AP
    • RNAscope™ VS Duplex Assay
    • BaseScope™ VS Reagent Kit – RED
    RNA-Protein Co-Detection Assay
    +
    • RNAscope HiPlex-IMC™ Co-Detection
    • Integrated Codetection Assay
    • Sequential RNA Protein Detection
    Software
    +
    • Overview
    • Aperio RNA ISH Algorithm
    • HALO® image analysis platform
    Controls & Accessories
    +
    • RNAscope™
    • BaseScope™
    • miRNAscope™
    • Accessories
    How to Order
    +
    • Ordering Instructions
    • What to Buy
  • Services +
    Professional Assay Services
    +
    • Our Services
    • Multiomic Services
    • Biomarker Assay Development
    • Cell & Gene Therapy Services
    • Clinical Assay Development
    • Tissue Bank & Sample Procurement
    • Image Analysis
    Benefits
    +
    • Your Benefits
    • Certified Providers
    How to Order
    +
    • Ordering Process
    • Contact Services
  • Areas of Research +
    Most Popular
    +
    • COVID-19 Coronavirus
    • Single Cell Analysis
    • Whole-Mount
    • Anatomic Pathology Panels
    • Neuroscience
    • Inflammation
    • Gene Therapy/AAV
    • Stem Cell
    • Immuno-oncology
    • Liver Research
    • Cardiovascular & Skeletal Muscle Research
    Cell & Gene Therapy
    +
    • Gene Therapy
    • Gene Therapy/AAV
    • siRNA/ASO
    • Cell Therapy
    Cancer
    +
    • Breast Cancer
    • EGFRvIII Splice Variant
    • HPV Related Cancer
    • Immuno-oncology
    • Lung Cancer
    • PDx
    • Prostate Cancer
    • Point Mutation
    • CDR3 for TCR
    Viral
    +
    • COVID-19 Coronavirus
    • HIV & SIV
    • Infectious Disease
    • Zika Virus
    Pathways
    +
    • AKT
    • JAK STAT
    • WNT B-Catenin
    Neuroscience
    +
    Neuroscience
    • Neural Development
    • Neuronal Cell Types
    • Learning and Memory
    • G-protein-coupled Receptors & Ion Channels
    • Post-mortem Brain Tissue
    Other
    +
    • Circular RNA
    • Gene Fusions
    • HT Transcript Validation
    • Long Non-coding RNA
    • RNAseq Validation
    • Single Cell Analysis
    • Splice Variant
    • miRNA
    RNA & Protein
    +
    • Antibody Challenges
    • Dual ISH + IHC Methods
    • No Antibodies
    • RNA & Protein Analysis
    Customer Innovations
    +
    • Dual RNA+DNA ISH
    • Very old FFPE ISH
    • Wholemount ISH
    Animal Models
    +
    • Any Species
    • Mouse Model
    • Preclincal Safety
  • Technology +
    Overview
    +
    • How it Works
    • Data Image Gallery
    • Technology Video
    • Webinars
    RNA Detection
    +
    • Why RNA?
    • RNA ISH and IHC
    Pretreatment Options
    +
    • RNAscope™ Pretreatment
    • PretreatPro™
    Spotlights
    +
    • Researchers Spotlights
    • RNA & DNA
    • WISH
    • FFPE
    • Testimonials
    Publications, Guides & Posters
    +
    • Search publications
    • RNAscope™ Reference Guide
    • RNAscope™ Data Analysis Guide
    • Download RNAscope™ Posters
  • Support +
    Overview
    +
    • Get Started
    • How to Order
    • Distributors
    • Contact Support
    Troubleshooting
    +
    • Troubleshooting Guide
    • FAQs
    • User Manuals, SDS and Product Inserts
    • Documents and Downloads
    Imaging Resource
    +
    • Image Analysis
    • Image Registration Software
    • QuPath
    • HALO® image analysis platform
    Learn More
    +
    • Webinars
    • Training Videos
  • Partners +
    Partners
    +
    • Overview
    Partners Directory
    +
    Automation Partners
    • Leica Biosystem
    • Roche Diagnostics
    Workflow Partners
    • NanoString
    Software Partners
    • indica labs
    Become a Partner
    +
    • Learn How
  • Diagnostics +
    Diagnostics
    +
    • Diagnostics
    • Literature
    • Diagnostics ASR Probes
    • Diagnostics CE-IVD Probes
    • Diagnostics CE-IVD Detection
    • Companion Diagnostics
  • Image Calendar +
    Image Calendar
    +
    • Image Contest
    • Data Image Gallery
Search

Probes for INS

ACD can configure probes for the various manual and automated assays for INS for RNAscope Assay, or for Basescope Assay compatible for your species of interest.

  • Probes for INS (0)
  • Kits & Accessories (0)
  • Support & Documents (0)
  • Publications (1023)
  • Image gallery (0)
Refine Probe List

Content for comparison

Gene

  • TBD (39) Apply TBD filter
  • Slc17a6 (28) Apply Slc17a6 filter
  • SLC32A1 (27) Apply SLC32A1 filter
  • vGlut2 (25) Apply vGlut2 filter
  • FOS (23) Apply FOS filter
  • Gad1 (22) Apply Gad1 filter
  • TH (22) Apply TH filter
  • tdTomato (22) Apply tdTomato filter
  • VGAT (20) Apply VGAT filter
  • Lgr5 (18) Apply Lgr5 filter
  • GFAP (17) Apply GFAP filter
  • Slc17a7 (17) Apply Slc17a7 filter
  • Axin2 (15) Apply Axin2 filter
  • DRD1 (15) Apply DRD1 filter
  • Sst (15) Apply Sst filter
  • Gad2 (15) Apply Gad2 filter
  • DRD2 (14) Apply DRD2 filter
  • SARS-CoV-2 (14) Apply SARS-CoV-2 filter
  • Rbfox3 (13) Apply Rbfox3 filter
  • PVALB (12) Apply PVALB filter
  • PDGFRA (12) Apply PDGFRA filter
  • Chat (12) Apply Chat filter
  • Pomc (12) Apply Pomc filter
  • egfp (11) Apply egfp filter
  • GLI1 (11) Apply GLI1 filter
  • CCK (10) Apply CCK filter
  • AGRP (10) Apply AGRP filter
  • PECAM1 (10) Apply PECAM1 filter
  • Penk (10) Apply Penk filter
  • OPRM1 (10) Apply OPRM1 filter
  • ACTA2 (9) Apply ACTA2 filter
  • Trpv1 (9) Apply Trpv1 filter
  • Cre (9) Apply Cre filter
  • Tmem119 (9) Apply Tmem119 filter
  • Sox9 (8) Apply Sox9 filter
  • CALCA (8) Apply CALCA filter
  • GLP1R (8) Apply GLP1R filter
  • MKI67 (8) Apply MKI67 filter
  • LEPR (8) Apply LEPR filter
  • WNT2 (8) Apply WNT2 filter
  • Sftpc (8) Apply Sftpc filter
  • Olig2 (8) Apply Olig2 filter
  • CD68 (7) Apply CD68 filter
  • Wnt5a (7) Apply Wnt5a filter
  • Spp1 (7) Apply Spp1 filter
  • Aldh1l1 (7) Apply Aldh1l1 filter
  • Npy (7) Apply Npy filter
  • PPIB (7) Apply PPIB filter
  • Phox2b (7) Apply Phox2b filter
  • Aif1 (7) Apply Aif1 filter

Product

  • (-) Remove RNAscope Multiplex Fluorescent Assay filter RNAscope Multiplex Fluorescent Assay (1023)

Research area

  • Neuroscience (486) Apply Neuroscience filter
  • Development (179) Apply Development filter
  • Cancer (90) Apply Cancer filter
  • Inflammation (80) Apply Inflammation filter
  • Stem Cells (44) Apply Stem Cells filter
  • Stem cell (33) Apply Stem cell filter
  • Metabolism (30) Apply Metabolism filter
  • Covid (28) Apply Covid filter
  • Infectious (26) Apply Infectious filter
  • CGT (16) Apply CGT filter
  • Aging (14) Apply Aging filter
  • lncRNA (13) Apply lncRNA filter
  • Other: Heart (11) Apply Other: Heart filter
  • Pain (11) Apply Pain filter
  • Other: Metabolism (10) Apply Other: Metabolism filter
  • Alzheimer's Disease (9) Apply Alzheimer's Disease filter
  • Behavior (9) Apply Behavior filter
  • behavioral (9) Apply behavioral filter
  • Other (9) Apply Other filter
  • Regeneration (9) Apply Regeneration filter
  • HIV (8) Apply HIV filter
  • Infectious Disease (8) Apply Infectious Disease filter
  • LncRNAs (8) Apply LncRNAs filter
  • Obesity (8) Apply Obesity filter
  • Addiction (7) Apply Addiction filter
  • Endocrinology (7) Apply Endocrinology filter
  • Fibrosis (7) Apply Fibrosis filter
  • Kidney (7) Apply Kidney filter
  • Liver (7) Apply Liver filter
  • Psychiatry (7) Apply Psychiatry filter
  • Stress (7) Apply Stress filter
  • Bone (6) Apply Bone filter
  • diabetes (6) Apply diabetes filter
  • Injury (6) Apply Injury filter
  • Lung (6) Apply Lung filter
  • Sleep (6) Apply Sleep filter
  • Anxiety (5) Apply Anxiety filter
  • Feeding Behavior (5) Apply Feeding Behavior filter
  • Heart (5) Apply Heart filter
  • Other: Endocrinology (5) Apply Other: Endocrinology filter
  • Progenitor Cells (5) Apply Progenitor Cells filter
  • Immunotherapy (4) Apply Immunotherapy filter
  • Memory (4) Apply Memory filter
  • Other: Kidney (4) Apply Other: Kidney filter
  • Other: Skin (4) Apply Other: Skin filter
  • Parkinson's Disease (4) Apply Parkinson's Disease filter
  • Reproductive Biology (4) Apply Reproductive Biology filter
  • Schizophrenia (4) Apply Schizophrenia filter
  • Single Cell (4) Apply Single Cell filter
  • Skin (4) Apply Skin filter

Category

  • Publications (1023) Apply Publications filter
A novel transgenic mouse model expressing primate-specific nuclear choline acetyltransferase: insights into potential cholinergic vulnerability

Scientific reports

2023 Feb 21

AlQot, HE;Rylett, RJ;
PMID: 36810877 | DOI: 10.1038/s41598-023-30155-4

The acetylcholine (ACh) synthesizing enzyme choline acetyltransferase (ChAT) is an important cholinergic neuronal marker whose levels and/or activity are reduced in physiological and pathological aging. One isoform of ChAT, 82-kDa ChAT, is expressed only in primates and found primarily in nuclei of cholinergic neurons in younger individuals, but this protein becomes mostly cytoplasmic with increasing age and in Alzheimer's disease (AD). Previous studies suggest that 82-kDa ChAT may be involved in regulating gene expression during cellular stress. Since it is not expressed in rodents, we developed a transgenic mouse model that expresses human 82-kDa ChAT under the control of an Nkx2.1 driver. Behavioral and biochemical assays were used to phenotype this novel transgenic model and elucidate the impact of 82-kDa ChAT expression. The 82-kDa ChAT transcript and protein were expressed predominantly in basal forebrain neurons and subcellular distribution of the protein recapitulated the age-related pattern found previously in human necropsy brains. Older 82-kDa ChAT-expressing mice presented with better age-related memory and inflammatory profiles. In summary, we established a novel transgenic mouse expressing 82-kDa ChAT that is valuable for studying the role of this primate-specific cholinergic enzyme in pathologies associated with cholinergic neuron vulnerability and dysfunction.
auts2 Features and Expression Are Highly Conserved during Evolution Despite Different Evolutionary Fates Following Whole Genome Duplication

Cells

2022 Aug 30

Merdrignac, C;Clément, AE;Montfort, J;Murat, F;Bobe, J;
PMID: 36078102 | DOI: 10.3390/cells11172694

The AUTS2 gene plays major roles during brain development and is associated with various neuropathologies including autism. Data in non-mammalian species are scarce, and the aim of our study was to provide a comprehensive analysis of auts2 evolution in teleost fish, which are widely used for in vivo functional analysis and biomedical purposes. Comparative genomics in 78 species showed that auts2a and auts2b originate from the teleost-specific whole genome duplication (TGD). auts2a, which is highly similar to human AUTS2, was almost systematically retained following TGD. In contrast, auts2b, which encodes for a shorter protein similar to a short human AUTS2 isoform, was lost more frequently and independently during evolution. RNA-seq analysis in 10 species revealed a highly conserved profile with predominant expression of both genes in the embryo, brain, and gonads. Based on protein length, conserved domains, and expression profiles, we speculate that the long human isoform functions were retained by auts2a, while the short isoform functions were retained by auts2a and/or auts2b, depending on the lineage/species. auts2a showed a burst in expression during medaka brain formation, where it was expressed in areas of the brain associated with neurodevelopmental disorders. Together, our data suggest a strong conservation of auts2 functions in vertebrates despite different evolutionary scenarios in teleosts.
Epidermal integrin α3β1 regulates tumor-derived proteases BMP-1, MMP-9 and MMP-3

JID Innovations

2021 Apr 01

Longmate, W;Miskin, R;Van De Water, L;DiPersio, C;
| DOI: 10.1016/j.xjidi.2021.100017

As the major cell surface receptors for the extracellular matrix, integrins regulate adhesion and migration, and have been shown to drive tumor growth and progression. Previous studies showed that mice lacking integrin α3β1 in the epidermis fail to form skin tumors during two-step chemical tumorigenesis, indicating a pro-tumorigenic role for α3β1. Furthermore, genetic ablation of α3β1 in established skin tumors caused their rapid regression, indicating an essential role in the maintenance of tumor growth. In our current study, analysis of immortalized keratinocyte lines and their conditioned media support a role for α3β1 in regulating the expression of several extracellular proteases of the keratinocyte secretome, namely BMP-1, MMP-9 and MMP-3. Moreover, immunofluorescence revealed reduced levels of each protease in α3β1-deficient tumors, and RNA in situ hybridization showed that their expression was correspondingly reduced in α3β1-deficient tumor cells in vivo. Bioinformatic analysis confirmed that expression of BMP1, MMP9, and MMP3 genes correlate with expression of ITGA3 (gene encoding the integrin α3 subunit) in human SCC, and that high ITGA3 and MMP3 associate with poor survival outcome in these patients. Overall, our findings identify α3β1 as a regulator of several proteases within the secretome of epidermal tumors, and as a potential therapeutic target.
Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes

Molecular and cellular endocrinology

2023 Apr 19

Drexler, S;Cai, C;Hartmann, AL;Moch, D;Gaitantzi, H;Ney, T;Kraemer, M;Chu, Y;Zheng, Y;Rahbari, M;Treffs, A;Reiser, A;Lenoir, B;Valous, NA;Jäger, D;Birgin, E;Sawant, TA;Li, Q;Xu, K;Dong, L;Otto, M;Itzel, T;Teufel, A;Gretz, N;Hawinkels, LJAC;Sánchez, A;Herrera, B;Schubert, R;Moshage, H;Reissfelder, C;Ebert, MPA;Rahbari, NN;Breitkopf-Heinlein, K;
PMID: 37085108 | DOI: 10.1016/j.mce.2023.111934

Bone morphogenetic protein (BMP)-9, a member of the TGFβ-family of cytokines, is believed to be mainly produced in the liver. The serum levels of BMP-9 were reported to be reduced in newly diagnosed diabetic patients and BMP-9 overexpression ameliorated steatosis in the high fat diet-induced obesity mouse model. Furthermore, injection of BMP-9 in mice enhanced expression of fibroblast growth factor (FGF)21. However, whether BMP-9 also regulates the expression of the related FGF19 is not clear. Because both FGF21 and 19 were described to protect the liver from steatosis, we have further investigated the role of BMP-9 in this context. We first analyzed BMP-9 levels in the serum of streptozotocin (STZ)-induced diabetic rats (a model of type I diabetes) and confirmed that BMP-9 serum levels decrease during diabetes. Microarray analyses of RNA samples from hepatic and intestinal tissue from BMP-9 KO- and wild-type mice (C57/Bl6 background) pointed to basal expression of BMP-9 in both organs and revealed a down-regulation of hepatic Fgf21 and intestinal Fgf19 in the KO mice. Next, we analyzed BMP-9 levels in a cohort of obese patients with or without diabetes. Serum BMP-9 levels did not correlate with diabetes, but hepatic BMP-9 mRNA expression negatively correlated with steatosis in those patients that did not yet develop diabetes. Likewise, hepatic BMP-9 expression also negatively correlated with serum LPS levels. In situ hybridization analyses confirmed intestinal BMP-9 expression. Intestinal (but not hepatic) BMP-9 mRNA levels were decreased with diabetes and positively correlated with intestinal E-Cadherin expression. In vitro studies using organoids demonstrated that BMP-9 directly induces FGF19 in gut but not hepatocyte organoids, whereas no evidence of a direct induction of hepatic FGF21 by BMP-9 was found. Consistent with the in vitro data, a correlation between intestinal BMP-9 and FGF19 mRNA expression was seen in the patients' samples. In summary, our data confirm that BMP-9 is involved in diabetes development in humans and in the control of the FGF-axis. More importantly, our data imply that not only hepatic but also intestinal BMP-9 associates with diabetes and steatosis development and controls FGF19 expression. The data support the conclusion that increased levels of BMP-9 would most likely be beneficial under pre-steatotic conditions, making supplementation of BMP-9 an interesting new approach for future therapies aiming at prevention of the development of a metabolic syndrome and liver steatosis.
Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging

Journal of Clinical Investigation

2021 Sep 01

Dias, J;Fabozzi, G;March, K;Asokan, M;Almasri, C;Fintzi, J;Promsote, W;Nishimura, Y;Todd, J;Lifson, J;Martin, M;Gama, L;Petrovas, C;Pegu, A;Mascola, J;Koup, R;
| DOI: 10.1172/jci151632

Immunological characterization of the Fiebig-equivalent stages of SHIVAD8-EO infection showed that, despite the observed differences in progression of infection between the challenge groups, the timing of virus-specific CD8+ T cell responses, as well as the viral load and virus distribution in the LNs, was concordant between the groups when assessed by Fiebig-equivalent staging. LN SHIVAD8-EO RNA+ cells were initially detected in both follicular and extrafollicular areas and mostly preceding peak plasma viremia at Fiebig-equivalent stage II, in agreement with previous studies (31, 41-44). Their levels increased proportionally to viral load in plasma, and seemed to decrease at Fiebig-equivalent stage VI when strong LN SIV-specific CD8+ T cell responses were detected. These responses, which appeared to develop at later stages than in the peripheral blood of acutely HIV-1-infected subjects (45), were predominantly characterized by production of the highly proinflammatory cytokine TNF and expression of CD107a, indicative of degranulation. In addition, levels of fCD8+ T cells, previously shown to be highly cytolytic ex vivo and able to mediate killing of HIV-infected target cells in vitro (31, 46), were higher at Fiebig-equivalent stage VI than stage V. LN NK cell levels also transiently increased at Fiebig-equivalent stage V. Thus, our data are consistent with the notion that, after peak plasma viremia during Fiebig-equivalent stages V and VI of SHIVAD8-EO infection, cytotoxic immune responses develop in the LNs and may lead to lysis of virus-infected cells and release of virions. In fact, LN SHIVAD8-EO RNA+ virions were almost absent at Fiebig-equivalent stage II when SHIVAD8-EO RNA+ cells, likely producing virions (47), were already present but CD8+ T cell responses were undetectable. However, virions were highly abundant in the follicles during Fiebig-equivalent stage VI when CD8+ T cell responses were stronger. Although there was no significant correlation between the levels of LN SHIVAD8-EO RNA+ cells and the virus-specific function of LN CD8+ T cells in our study, possibly because of limited sample size and data variation between animals, previous studies reported in situ observation of CD8+ T cells expressing T cell intracellular antigen-1 (TIA-1) or perforin (48, 49) and increased activation of cytotoxic cells (50) in the LNs of HIV-1-infected subjects. Furthermore, CD8+ T cells with HIV- or SIV-specific killing activity in vitro were detected in the LNs, splenic white pulp, and tonsil GCs of HIV-1-infected subjects (46, 51), and in the LNs of SIV-infected NHPs (31, 52, 53). Also, NK cells were shown to accumulate in the LNs of African green monkeys during nonpathogenic SIV infection, where they played an important role in the control of viral replication (54).
Studies in Zebra Fish and Rat Models Support Dual Blockade of EP2 and EP4 (Prostaglandin E2 Receptors Type 2 and 4) for Renoprotection in Glomerular Hyperfiltration and Albuminuria

Hypertension (Dallas, Tex. : 1979)

2023 Jan 30

Kourpa, A;Schulz, A;Mangelsen, E;Kaiser-Graf, D;Koppers, N;Stoll, M;Rothe, M;Bader, M;Purfürst, B;Kunz, S;Gladytz, T;Niendorf, T;Bachmann, S;Mutig, K;Bolbrinker, J;Panáková, D;Kreutz, R;
PMID: 36715011 | DOI: 10.1161/HYPERTENSIONAHA.122.20392

Glomerular hyperfiltration (GH) is an important mechanism in the development of albuminuria in hypertension. Upregulation of COX2 (cyclooxygenase 2) and prostaglandin E2 (PGE2) was linked to podocyte damage in GH. We explored the potential renoprotective effects of either separate or combined pharmacological blockade of EP2 (PGE2 receptor type 2) and EP4 (PGE2 receptor type 4) in GH.We conducted in vivo studies in a transgenic zebra fish model (Tg[fabp10a:gc-EGFP]) suitable for analysis of glomerular filtration barrier function and a genetic rat model with GH, albuminuria, and upregulation of PGE2. Similar pharmacological interventions and primary outcome analysis on albuminuria phenotype development were conducted in both model systems.Stimulation of zebra fish embryos with PGE2 induced an albuminuria-like phenotype, thus mimicking the suggested PGE2 effects on glomerular filtration barrier dysfunction. Both separate and combined blockade of EP2 and EP4 reduced albuminuria phenotypes in zebra fish and rat models. A significant correlation between albuminuria and podocyte damage in electron microscopy imaging was identified in the rat model. Dual blockade of both receptors showed a pronounced synergistic suppression of albuminuria. Importantly, this occurred without changes in arterial blood pressure, glomerular filtration rate, or tissue oxygenation in magnetic resonance imaging, while RNA sequencing analysis implicated a potential role of circadian clock genes.Our findings confirm a role of PGE2 in the development of albuminuria in GH and support the renoprotective potential of combined pharmacological blockade of EP2 and EP4 receptors. These data support further translational research to explore this therapeutic option and a possible role of circadian clock genes.
Acan downregulation in parvalbumin GABAergic cells reduces spontaneous recovery of fear memories

Molecular psychiatry

2023 May 02

Lavertu-Jolin, M;Chattopadhyaya, B;Chehrazi, P;Carrier, D;Wünnemann, F;Leclerc, S;Dumouchel, F;Robertson, D;Affia, H;Saba, K;Gopal, V;Patel, AB;Andelfinger, G;Pineyro, G;Di Cristo, G;
PMID: 37131076 | DOI: 10.1038/s41380-023-02085-0

While persistence of fear memories is essential for survival, a failure to inhibit fear in response to harmless stimuli is a feature of anxiety disorders. Extinction training only temporarily suppresses fear memory recovery in adults, but it is highly effective in juvenile rodents. Maturation of GABAergic circuits, in particular of parvalbumin-positive (PV+) cells, restricts plasticity in the adult brain, thus reducing PV+ cell maturation could promote the suppression of fear memories following extinction training in adults. Epigenetic modifications such as histone acetylation control gene accessibility for transcription and help couple synaptic activity to changes in gene expression. Histone deacetylase 2 (Hdac2), in particular, restrains both structural and functional synaptic plasticity. However, whether and how Hdac2 controls the maturation of postnatal PV+ cells is not well understood. Here, we show that PV+- cell specific Hdac2 deletion limits spontaneous fear memory recovery in adult mice, while enhancing PV+ cell bouton remodeling and reducing perineuronal net aggregation around PV+ cells in prefrontal cortex and basolateral amygdala. Prefrontal cortex PV+ cells lacking Hdac2, show reduced expression of Acan, a critical perineuronal net component, which is rescued by Hdac2 re-expression. Pharmacological inhibition of Hdac2 before extinction training is sufficient to reduce both spontaneous fear memory recovery and Acan expression in wild-type adult mice, while these effects are occluded in PV+-cell specific Hdac2 conditional knockout mice. Finally, a brief knock-down of Acan expression mediated by intravenous siRNA delivery before extinction training but after fear memory acquisition is sufficient to reduce spontaneous fear recovery in wild-type mice. Altogether, these data suggest that controlled manipulation of PV+ cells by targeting Hdac2 activity, or the expression of its downstream effector Acan, promotes the long-term efficacy of extinction training in adults.
Identification and functional modelling of plausibly causative cis-regulatory variants in a highly-selected cohort with X-linked intellectual disability

PloS one

2021 Aug 13

Bengani, H;Grozeva, D;Moyon, L;Bhatia, S;Louros, SR;Hope, J;Jackson, A;Prendergast, JG;Owen, LJ;Naville, M;Rainger, J;Grimes, G;Halachev, M;Murphy, LC;Spasic-Boskovic, O;van Heyningen, V;Kind, P;Abbott, CM;Osterweil, E;Raymond, FL;Roest Crollius, H;FitzPatrick, DR;
PMID: 34388204 | DOI: 10.1371/journal.pone.0256181

Identifying causative variants in cis-regulatory elements (CRE) in neurodevelopmental disorders has proven challenging. We have used in vivo functional analyses to categorize rigorously filtered CRE variants in a clinical cohort that is plausibly enriched for causative CRE mutations: 48 unrelated males with a family history consistent with X-linked intellectual disability (XLID) in whom no detectable cause could be identified in the coding regions of the X chromosome (chrX). Targeted sequencing of all chrX CRE identified six rare variants in five affected individuals that altered conserved bases in CRE targeting known XLID genes and segregated appropriately in families. Two of these variants, FMR1CRE and TENM1CRE, showed consistent site- and stage-specific differences of enhancer function in the developing zebrafish brain using dual-color fluorescent reporter assay. Mouse models were created for both variants. In male mice Fmr1CRE induced alterations in neurodevelopmental Fmr1 expression, olfactory behavior and neurophysiological indicators of FMRP function. The absence of another likely causative variant on whole genome sequencing further supported FMR1CRE as the likely basis of the XLID in this family. Tenm1CRE mice showed no phenotypic anomalies. Following the release of gnomAD 2.1, reanalysis showed that TENM1CRE exceeded the maximum plausible population frequency of a XLID causative allele. Assigning causative status to any ultra-rare CRE variant remains problematic and requires disease-relevant in vivo functional data from multiple sources. The sequential and bespoke nature of such analyses renders them time-consuming and challenging to scale for routine clinical use.
Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.

Alzheimers Res Ther.

2019 Feb 02

Magno L, Lessard CB, Martins M, Lang V, Cruz P, Asi Y, Katan M, Bilsland J, Lashley T, Chakrabarty P, Golde TE, Whiting PJ.
PMID: 30711010 | DOI: 10.1186/s13195-019-0469-0

Abstract

BACKGROUND:

Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer's disease (LOAD). Amongst these, a polymorphism in phospholipase C-gamma 2 (PLCG2) P522R has been reported to be protective against LOAD. PLC enzymes are key elements in signal transmission networks and are potentially druggable targets. PLCG2 is highly expressed in the hematopoietic system. Hypermorphic mutations in PLCG2 in humans have been reported to cause autoinflammation and immune disorders, suggesting a key role for this enzyme in the regulation of immune cell function.

METHODS:

We assessed PLCG2 distribution in human and mouse brain tissue via immunohistochemistry and in situ hybridization. We transfected heterologous cell systems (COS7 and HEK293T cells) to determine the effect of the P522R AD-associated variant on enzymatic function using various orthogonal assays, including a radioactive assay, IP-One ELISA, and calcium assays.

RESULTS:

PLCG2 expression is restricted primarily to microglia and granule cells of the dentate gyrus. Plcg2 mRNA is maintained in plaque-associated microglia in the cerebral tissue of an AD mouse model. Functional analysis of the p.P522R variant demonstrated a small hypermorphic effect of the mutation on enzyme function.

CONCLUSIONS:

The PLCG2 P522R variant is protective against AD. We show that PLCG2 is expressed in brain microglia, and the p.P522R polymorphism weakly increases enzyme function. These data suggest that activation of PLCγ2 and not inhibition could be therapeutically beneficial in AD. PLCγ2 is therefore a potential target for modulating microglia function in AD, and a small molecule drug that weakly activates PLCγ2 may be one potential therapeutic approach.

Alpha cell TXNIP deletion improves diabetes-associated hyperglycemia and hyperglucagonemia

Endocrinology

2022 Aug 12

Lu, B;Chen, J;Xu, G;Grayson, TB;Jing, G;Jo, S;Shalev, A;
PMID: 35957590 | DOI: 10.1210/endocr/bqac133

Thioredoxin-interacting protein (Txnip) has emerged as a key factor in pancreatic beta cell biology and its upregulation by glucose and diabetes contributes to the impairment in functional beta cell mass and glucose homeostasis. In addition, beta cell deletion of Txnip protects against diabetes in different mouse models. However, while Txnip is ubiquitously expressed, its role in pancreatic alpha cells has remained elusive. We therefore now generated an alpha cell Txnip knockout (aTKO) mouse and assessed the effects on glucose homeostasis. While no significant changes were observed on regular chow, after a 30-week high-fat diet, aTKO animals showed improvement in glucose tolerance and lower blood glucose levels compared to their control littermates. Moreover, in the context of streptozotocin (STZ)-induced diabetes, aTKO mice showed significantly lower blood glucose levels compared to controls. While serum insulin levels were reduced in both control and aTKO mice, STZ-diabetes significantly increased glucagon levels in control mice, but this effect was blunted in aTKO mice. Moreover, glucagon secretion from aTKO islets was >2-fold lower than from control islets, while insulin secretion was unchanged in aTKO islets. At the same time, no change in alpha cell or beta cell numbers or mass was observed and glucagon and insulin expression and content were comparable in isolated islets from aTKO and control mice. Thus, together the current studies suggest that downregulation of alpha cell Txnip is associated with reduced glucagon secretion and that this may contribute to the glucose-lowering effects observed in diabetic aTKO mice.
Reward and aversion processing by input-defined parallel nucleus accumbens circuits in mice

Nature communications

2022 Oct 21

Zhou, K;Xu, H;Lu, S;Jiang, S;Hou, G;Deng, X;He, M;Zhu, Y;
PMID: 36271048 | DOI: 10.1038/s41467-022-33843-3

The nucleus accumbens (NAc) is critical in mediating reward seeking and is also involved in negative emotion processing, but the cellular and circuitry mechanisms underlying such opposing behaviors remain elusive. Here, using the recently developed AAV1-mediated anterograde transsynaptic tagging technique in mice, we show that NAc neurons receiving basolateral amygdala inputs (NAcBLA) promote positive reinforcement via disinhibiting dopamine neurons in the ventral tegmental area (VTA). In contrast, NAc neurons receiving paraventricular thalamic inputs (NAcPVT) innervate GABAergic neurons in the lateral hypothalamus (LH) and mediate aversion. Silencing the synaptic output of NAcBLA neurons impairs reward seeking behavior, while silencing of NAcPVT or NAcPVT→LH pathway abolishes aversive symptoms of opiate withdrawal. Our results elucidate the afferent-specific circuit architecture of the NAc in controlling reward and aversion.
Convergent deployment of ancestral functions during the evolution of mammalian flight membranes

Science advances

2023 Mar 24

Feigin, CY;Moreno, JA;Ramos, R;Mereby, SA;Alivisatos, A;Wang, W;van Amerongen, R;Camacho, J;Rasweiler, JJ;Behringer, RR;Ostrow, B;Plikus, MV;Mallarino, R;
PMID: 36961889 | DOI: 10.1126/sciadv.ade7511

Lateral flight membranes, or patagia, have evolved repeatedly in diverse mammalian lineages. While little is known about patagium development, its recurrent evolution may suggest a shared molecular basis. By combining transcriptomics, developmental experiments, and mouse transgenics, we demonstrate that lateral Wnt5a expression in the marsupial sugar glider (Petaurus breviceps) promotes the differentiation of its patagium primordium. We further show that this function of Wnt5a reprises ancestral roles in skin morphogenesis predating mammalian flight and has been convergently used during patagium evolution in eutherian bats. Moreover, we find that many genes involved in limb development have been redeployed during patagium outgrowth in both the sugar glider and bat. Together, our findings reveal that deeply conserved genetic toolkits contribute to the evolutionary transition to flight in mammals.

Pages

  • « first
  • ‹ previous
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • next ›
  • last »
X
Description
sense
Example: Hs-LAG3-sense
Standard probes for RNA detection are in antisense. Sense probe is reverse complent to the corresponding antisense probe.
Intron#
Example: Mm-Htt-intron2
Probe targets the indicated intron in the target gene, commonly used for pre-mRNA detection
Pool/Pan
Example: Hs-CD3-pool (Hs-CD3D, Hs-CD3E, Hs-CD3G)
A mixture of multiple probe sets targeting multiple genes or transcripts
No-XSp
Example: Hs-PDGFB-No-XMm
Does not cross detect with the species (Sp)
XSp
Example: Rn-Pde9a-XMm
designed to cross detect with the species (Sp)
O#
Example: Mm-Islr-O1
Alternative design targeting different regions of the same transcript or isoforms
CDS
Example: Hs-SLC31A-CDS
Probe targets the protein-coding sequence only
EnEmProbe targets exons n and m
En-EmProbe targets region from exon n to exon m
Retired Nomenclature
tvn
Example: Hs-LEPR-tv1
Designed to target transcript variant n
ORF
Example: Hs-ACVRL1-ORF
Probe targets open reading frame
UTR
Example: Hs-HTT-UTR-C3
Probe targets the untranslated region (non-protein-coding region) only
5UTR
Example: Hs-GNRHR-5UTR
Probe targets the 5' untranslated region only
3UTR
Example: Rn-Npy1r-3UTR
Probe targets the 3' untranslated region only
Pan
Example: Pool
A mixture of multiple probe sets targeting multiple genes or transcripts

Enabling research, drug development (CDx) and diagnostics

Contact Us
  • Toll-free in the US and Canada
  • +1877 576-3636
  • 
  • 
  • 
Company
  • Overview
  • Leadership
  • Careers
  • Distributors
  • Quality
  • News & Events
  • Webinars
  • Patents
Products
  • RNAscope or BaseScope
  • Target Probes
  • Controls
  • Manual assays
  • Automated Assays
  • Accessories
  • Software
  • How to Order
Research
  • Popular Applications
  • Cancer
  • Viral
  • Pathways
  • Neuroscience
  • Other Applications
  • RNA & Protein
  • Customer Innovations
  • Animal Models
Technology
  • Overview
  • RNA Detection
  • Spotlight Interviews
  • Publications & Guides
Assay Services
  • Our Services
  • Biomarker Assay Development
  • Cell & Gene Therapy Services
  • Clinical Assay Development
  • Tissue Bank & Sample Procurement
  • Image Analysis
  • Your Benefits
  • How to Order
Diagnostics
  • Diagnostics
  • Companion Diagnostics
Support
  • Getting started
  • Contact Support
  • Troubleshooting Guide
  • FAQs
  • Manuals, SDS & Inserts
  • Downloads
  • Webinars
  • Training Videos

Visit Bio-Techne and its other brands

  • bio-technie
  • protein
  • bio-spacific
  • rd
  • novus
  • tocris
© 2025 Advanced Cell Diagnostics, Inc.
  • Terms and Conditions of Sale
  • Privacy Policy
  • Security
  • Email Preferences
  • 
  • 
  • 

For Research Use Only. Not for diagnostic use. Refer to appropriate regulations. RNAscope is a registered trademark; and HybEZ, EZ-Batch and DNAscope are trademarks of Advanced Cell Diagnostics, Inc. in the United States and other countries. All rights reserved. ©2025 Advanced Cell Diagnostics, Inc.

 

Contact Us / Request a Quote
Download Manuals
Request a PAS Project Consultation
Order online at
bio-techne.com
OK
X
Contact Us

Complete one of the three forms below and we will get back to you.

For Quote Requests, please provide more details in the Contact Sales form below

  • Contact Sales
  • Contact Support
  • Contact Services
  • Offices

Advanced Cell Diagnostics

Our new headquarters office starting May 2016:

7707 Gateway Blvd.  
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798

 

Bio-Techne

19 Barton Lane  
Abingdon Science Park
Abingdon
OX14 3NB
United Kingdom
Phone 2: +44 1235 529449
Fax: +44 1235 533420

 

Advanced Cell Diagnostics China

20F, Tower 3,
Raffles City Changning Office,
1193 Changning Road, Shanghai 200051

021-52293200
info.cn@bio-techne.com
Web: www.acdbio.com/cn

For general information: Info.ACD@bio-techne.com
For place an order: order.ACD@bio-techne.com
For product support: support.ACD@bio-techne.com
For career opportunities: hr.ACD@bio-techne.com

See Distributors
×

You have already Quick ordered an Item in your cart . If you want to add a new item , Quick ordered Item will be removed form your cart. Do You want to continue?

OK Cancel
Need help?

How can we help you?